TOVX

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Wall Street analysts forecast TOVX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOVX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Theriva Biologics Inc revenue for the last quarter amounts to -4.44M USD, decreased -11.83 % YoY.

Theriva Biologics Inc. EPS for the last quarter amounts to -4338000.00 USD, decreased % YoY.

Theriva Biologics Inc (TOVX) has 22 emplpoyees as of December 17 2025.

Today TOVX has the market capitalization of 6.92M USD.